In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...
GSK stock declined 3% despite beating Q1 earnings estimates. Analysts note legal provisions contributed half the beat.
GSK posted above-forecast first-quarter profits on Wednesday, boosted by robust demand for its specialist HIV and oncology ...
Zacks Investment Research on MSN
GSK Q1 earnings beat estimates, specialty medicines drive sales growth
GSK plc GSK reported first-quarter 2026 core earnings of $1.26 per American depositary share (ADS), which beat the Zacks ...
Core operating profit for the three months ended March 31 rose 10% at constant exchange rates (CER) to £2.65 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results